Smith & Nephew SNATS, Inc. (NYSE:SNN) Receives Consensus Recommendation of "Hold" from Brokerages

Key Points

• Smith & Nephew SNATS has a consensus “Hold” rating from six brokerages: five analysts rated it Hold and one rated it Buy. The average 12-month price target is $30.925.
• Recent analyst actions were mixed but generally cautious, including downgrades from Kepler Capital Markets and Weiss Ratings and a target-price cut from Canaccord Genuity; Goldman Sachs reaffirmed a Buy rating.
• Institutional investors own 25.64% of the company, while the stock recently traded at $31.53, within its one-year range of $28.56 to $38.79.

Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN - Get Free Report) have received a consensus rating of "Hold" from the six brokerages that are currently covering the stock, MarketBeat.com reports. Five investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $30.9250.

A number of analysts recently issued reports on the company. Weiss Ratings downgraded Smith & Nephew SNATS from a "hold (c+)" rating to a "hold (c)" rating in a research report on Thursday, June 11th. Kepler Capital Markets cut shares of Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a research report on Thursday, June 4th. Canaccord Genuity Group reduced their target price on shares of Smith & Nephew SNATS from $32.00 to $30.00 and set a "hold" rating on the stock in a research note on Monday, May 11th. The Goldman Sachs Group reissued a "buy" rating on shares of Smith & Nephew SNATS in a research note on Monday, May 25th. Finally, Sanford C. Bernstein set a $31.85 target price on shares of Smith & Nephew SNATS in a report on Monday, May 11th.

Institutional Trading of Smith & Nephew SNATS

Institutional investors have recently added to or reduced their stakes in the company. Garner Asset Management Corp purchased a new position in shares of Smith & Nephew SNATS during the fourth quarter valued at approximately $27,000. Arax Advisory Partners raised its holdings in shares of Smith & Nephew SNATS by 142.6% in the fourth quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider's stock worth $32,000 after buying an additional 569 shares during the period. Advisors Asset Management Inc. purchased a new stake in shares of Smith & Nephew SNATS in the fourth quarter worth approximately $36,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Smith & Nephew SNATS in the third quarter worth approximately $41,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Smith & Nephew SNATS during the 4th quarter worth approximately $43,000. Institutional investors own 25.64% of the company's stock.

Smith & Nephew SNATS Stock Performance

Shares of Smith & Nephew SNATS stock opened at $31.53 on Monday. The company has a current ratio of 2.57, a quick ratio of 1.25 and a debt-to-equity ratio of 0.60. The stock has a 50 day moving average price of $30.42 and a 200-day moving average price of $32.19. Smith & Nephew SNATS has a one year low of $28.56 and a one year high of $38.79.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.